Use of bevacizumab for patients with International Federation of Gynecology and Obstetrics stage IIIB to IV epithelial ovarian cancer undergoing primary debulking surgery and its association with oncologic outcomes: a Cancer Registry study
Bevacizumab is frequently used in primary debulking surgery for advanced ovarian cancer. Survival benefits are mainly observed in patients with residual disease, while PARP inhibitor therapy may influence these effects. Real-world evidence complements clinical trials and informs treatment decisions.
Authors
- Philipp Morakis (ORCID: https://orcid.org/0009-0005-2591-3273)
- Daria B. Kokh (ORCID: https://orcid.org/0000-0002-4687-6572)
- Irina Surovtsova (ORCID: https://orcid.org/0009-0003-4263-6250)
- Katharina Smetanay (ORCID: https://orcid.org/0000-0003-2881-5183)
- Oliver Zivanovic (ORCID: https://orcid.org/0000-0003-1305-4991)
- Georg Sauer
- André Pfob (ORCID: https://orcid.org/0000-0001-6140-9895)
- Andreas Schneeweiß (ORCID: https://orcid.org/0000-0002-2429-4512)
Institutions
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- Robert Bosch Hospital (DE)
- National Center for Tumor Diseases (DE)
- Baden-Wuerttemberg Cooperative State University (DE)
Publication Details
- Journal
- International Journal of Gynecological Cancer
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1016/j.ijgc.2025.102770
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00